{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T02:29:14Z","timestamp":1787192954074,"version":"build-2736575974"},"reference-count":70,"publisher":"Bioscientifica","issue":"12","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["eor.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,12,1]]},"abstract":"<jats:p>\n                    <jats:list list-type=\"bullet\">\n                      <jats:list-item>\n                        <jats:p>Denosumab is a fully humanised monoclonal antibody to RANK ligand, inhibiting the RANK\u2013RANKL pathway. It promotes the apoptosis of osteoclast-like giant cells, a secondary ossification and connective tissue formation.<\/jats:p>\n                      <\/jats:list-item>\n                      <jats:list-item>\n                        <jats:p>Given its high efficacy, denosumab is the standard treatment of unresectable or metastatic giant cell tumour of bone (GCTB) requiring morbid surgery.<\/jats:p>\n                      <\/jats:list-item>\n                      <jats:list-item>\n                        <jats:p>Neoadjuvant administration of denosumab may be justified to enable the resection of the tumour in certain cases; it should be considered, however, with caution for joint-saving surgery due to high local recurrence rates.<\/jats:p>\n                      <\/jats:list-item>\n                      <jats:list-item>\n                        <jats:p>In cases of unresectable or metastatic GCTB, however, denosumab treatment should be administered for years or even as a lifelong therapy. This poses many yet unanswered questions concerning the frequency of denosumab treatment as well as the ratio of the adverse events in the following years.<\/jats:p>\n                      <\/jats:list-item>\n                      <jats:list-item>\n                        <jats:p>\n                          Denosumab suppresses, not directly targets, the neoplastic stromal cells of GCTB. Ongoing\n                          <jats:italic>in vitro<\/jats:italic>\n                          studies suggest that other drugs alone or in combination (e.g. sunitinib) with denosumab may target both the neoplastic and the giant cells.\n                        <\/jats:p>\n                      <\/jats:list-item>\n                      <jats:list-item>\n                        <jats:p>Promising results have been reported regarding the off-label use of denosumab in other giant cell-rich tumours\/tumour-like lesions, i.e. aneurysmal bone cysts and central giant cell granulomas. Data are derived, however, mostly from case reports and case series. Large prospective clinical trials are needed to evaluate the role and also the side effects of denosumab in the treatment of these rare diseases.<\/jats:p>\n                      <\/jats:list-item>\n                    <\/jats:list>\n                  <\/jats:p>","DOI":"10.1530\/eor-23-0138","type":"journal-article","created":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T08:12:40Z","timestamp":1701418360000},"page":"895-905","update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-16","source":"Crossref","is-referenced-by-count":9,"title":["Current indications for denosumab in benign bone tumours"],"prefix":"10.1530","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7706-5679","authenticated-orcid":true,"given":"Antal","family":"Imre","sequence":"first","affiliation":[{"name":"Department of Orthopaedics, Semmelweis University, Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e1pi","family":"Zolt\u00e1n","sequence":"additional","affiliation":[{"name":"Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Szendr\u0151i","family":"Mikl\u00f3s","sequence":"additional","affiliation":[{"name":"Department of Orthopaedics, Semmelweis University, Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","reference":[{"key":"bib1","series-title":"Pathology Oncology Research","first-page":"1610633","article-title":"The activation of PDGFR\u03b2 on mononuclear stromal\/tumor cells in giant cell tumor of bone after denosumab treatment. An immunohistochemical study of five cases","volume":"28","author":"Antal","year":"2022","unstructured":"Antal IP\u00e1pai ZSzendr\u0151i MPerlaky TDezs\u0151 KLippai Z & S\u00e1pi Z. The activation of PDGFR\u03b2 on mononuclear stromal\/tumor cells in giant cell tumor of bone after denosumab treatment. An immunohistochemical study of five cases. Pathology Oncology Research2022281610633. (https:\/\/doi.org\/10.3389\/pore.2022.1610633)"},{"key":"bib2","series-title":"Radiotherapy and Oncology","first-page":"194","article-title":"The effect of radiotherapy, and radiotherapy combined with bisphosphonates or RANK ligand inhibitors on bone quality in bone metastases. A systematic review","volume":"119","author":"Groenen","year":"2016","unstructured":"Groenen KHPouw MHHannink GHosman AJvan der Linden YMVerdonschot N & Tanck E. The effect of radiotherapy, and radiotherapy combined with bisphosphonates or RANK ligand inhibitors on bone quality in bone metastases. A systematic review. Radiotherapy and Oncology2016119194\u2013201. (https:\/\/doi.org\/10.1016\/j.radonc.2016.03.001)"},{"key":"bib3","series-title":"Lancet. Oncology","first-page":"60","article-title":"Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial","volume":"21","author":"Coleman","year":"2020","unstructured":"Coleman RFinkelstein DMBarrios CMartin MIwata HHegg RGlaspy JPeria\u00f1ez AMTonkin KDeleu I, Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial. Lancet. Oncology20202160\u201372. (https:\/\/doi.org\/10.1016\/S1470-2045(1930687-4)"},{"key":"bib4","series-title":"WHO Classification of Tumours of Soft Tissue and Bone","first-page":"440","article-title":"Giant cell tumour of bone","author":"Flanagan","year":"2020","unstructured":"Flanagan AMLarousserie FO\u2019Donell PG & Yoshida A. Giant cell tumour of bone. In WHO Classification of Tumours of Soft Tissue and Bone5th ed., pp. 440\u2013446. Lyon, France: IARC Press2020."},{"key":"bib5","series-title":"Heidelberg","first-page":"652","author":"Freyschmidt","year":"2010","unstructured":"Freyschmidt JOstertag H & Knochentumoren JGHeidelberg4th ed., pp. 652\u2013692. Berlin: Springer2010."},{"key":"bib6","series-title":"Journal of Bone and Joint Surgery. American Volume","first-page":"1999","article-title":"Regional variation and challenges in estimating the incidence of giant cell tumor of bone","volume":"96","author":"Liede","year":"2014","unstructured":"Liede ABach BAStryker SHernandez RKSobocki PBennett B & Wong SS. Regional variation and challenges in estimating the incidence of giant cell tumor of bone. Journal of Bone and Joint Surgery. American Volume2014961999\u20132007. (https:\/\/doi.org\/10.2106\/JBJS.N.00367)"},{"key":"bib7","series-title":"Journal of Orthopaedic Science","first-page":"581","article-title":"Giant cell tumour of bone: an analysis of 139 Indian patients","volume":"16","author":"Saikia","year":"2011","unstructured":"Saikia KCBhuyan SKBorgohain MSaikia SPBora A & Ahmed F. Giant cell tumour of bone: an analysis of 139 Indian patients. Journal of Orthopaedic Science201116581\u2013588. (https:\/\/doi.org\/10.1007\/s00776-011-0033-7)"},{"key":"bib8","series-title":"Cancer Research","first-page":"257","article-title":"Giant cell tumour and chondrosarcomas: grading, treatment and results (studies on 209 and 131 cases)","volume":"54","author":"Campanacci","year":"1976","unstructured":"Campanacci M. Giant cell tumour and chondrosarcomas: grading, treatment and results (studies on 209 and 131 cases). Cancer Research197654257.(https:\/\/doi.org\/10.1007\/978-3-642-80997-2_2)"},{"key":"bib9","series-title":"Human Pathology","first-page":"945","article-title":"Phenotypic and molecular studies of giant-cell tumors of bone and soft tissue","volume":"36","author":"Lau","year":"2005","unstructured":"Lau YSSabokbar AGibbons CLGiele H & Athanasou N. Phenotypic and molecular studies of giant-cell tumors of bone and soft tissue. Human Pathology200536945\u2013954. (https:\/\/doi.org\/10.1016\/j.humpath.2005.07.005)"},{"key":"bib10","series-title":"International Orthopaedics","first-page":"315","article-title":"The prognostic significance of DNA cytophotometry and proliferation index (Ki-67) in giant cell tumors of bone","volume":"23","author":"Antal","year":"1999","unstructured":"Antal IS\u00e1pi Z & Szendr\u00f6i M. The prognostic significance of DNA cytophotometry and proliferation index (Ki-67) in giant cell tumors of bone. International Orthopaedics199923315\u2013319. (https:\/\/doi.org\/10.1007\/s002640050381)"},{"key":"bib11","series-title":"Genes, Chromosomes and Cancer","first-page":"468","article-title":"Genomic instability in giant cell tumor of bone. A study of 52 cases using DNA ploidy, relocalization FISH, and array-CGH analysis","volume":"48","author":"Moskovszky","year":"2009","unstructured":"Moskovszky LSzuhai KKren\u00e1cs THogendoorn PCSzendroi MBenassi MSKopper LF\u00fcle T & S\u00e1pi Z. Genomic instability in giant cell tumor of bone. A study of 52 cases using DNA ploidy, relocalization FISH, and array-CGH analysis. Genes, Chromosomes and Cancer200948468\u2013479. (https:\/\/doi.org\/10.1002\/gcc.20656)"},{"key":"bib12","series-title":"Nature Genetics","first-page":"1479","article-title":"Flanagan AM. Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone","volume":"45","author":"Behjati","year":"2013","unstructured":"Behjati STarpey PSPresneau NScheipl SPillay NVan Loo PWedge DCCooke SLGundem GDavies H, Flanagan AM. Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone. Nature Genetics2013451479\u20131482. (https:\/\/doi.org\/10.1038\/ng.2814)."},{"key":"bib13","series-title":"Cancers (Basel)","first-page":"5119","article-title":"Cell Biology of Giant Cell Tumour of Bone: crosstalk between m\/wt Nucleosome H3.3, Telomeres and Osteoclastogenesis","volume":"13","author":"Forsyth","year":"2021","unstructured":"Forsyth RGKren\u00e1cs TAthanasou N & Hogendoorn PCW. Cell Biology of Giant Cell Tumour of Bone: crosstalk between m\/wt Nucleosome H3.3, Telomeres and Osteoclastogenesis. Cancers (Basel)2021135119. (https:\/\/doi.org\/10.3390\/cancers13205119)"},{"key":"bib14","series-title":"Journal of Bone and Joint Surgery. British Volume","first-page":"5","article-title":"Giant-cell tumour of bone","volume":"86","author":"Szendr\u00f6i","year":"2004","unstructured":"Szendr\u00f6i M. Giant-cell tumour of bone. Journal of Bone and Joint Surgery. British Volume2004865\u201312. (https:\/\/doi.org\/10.1302\/0301-620X.86B1.14053)"},{"key":"bib15","series-title":"International Orthopaedics","first-page":"499","article-title":"Histologically verified lung metastases in benign giant cell tumours--14 cases from a single institution","volume":"30","author":"Dominkus","year":"2006","unstructured":"Dominkus MRuggieri PBertoni FBriccoli APicci PRocca M & Mercuri M. Histologically verified lung metastases in benign giant cell tumours--14 cases from a single institution. International Orthopaedics200630499\u2013504. (https:\/\/doi.org\/10.1007\/s00264-006-0204-x)"},{"key":"bib16","series-title":"Journal of Bone and Joint Surgery. American Volume","first-page":"420","article-title":"Risk factors for pulmonary metastases from giant cell tumor of bone","volume":"97","author":"Chan","year":"2015","unstructured":"Chan CMAdler ZReith JD & Gibbs CPJr. Risk factors for pulmonary metastases from giant cell tumor of bone. Journal of Bone and Joint Surgery. American Volume201597420\u2013428. (https:\/\/doi.org\/10.2106\/JBJS.N.00678)"},{"key":"bib17","series-title":"Technology in Cancer Research and Treatment","first-page":"1533033819840000","article-title":"Malignancy in giant cell tumor of bone: a review of the literature","volume":"18","author":"Palmerini","year":"2019","unstructured":"Palmerini EPicci PReichardt P & Downey G. Malignancy in giant cell tumor of bone: a review of the literature. Technology in Cancer Research and Treatment2019181533033819840000. (https:\/\/doi.org\/10.1177\/1533033819840000)"},{"key":"bib18","series-title":"Journal of Bone Oncology","first-page":"100334","article-title":"Malignancy in giant cell tumor of bone in the extremities","volume":"26","author":"Liu","year":"2020","unstructured":"Liu WChan CMGong LBui MMHan GLetson GDYang Y and Niu X. Malignancy in giant cell tumor of bone in the extremities. Journal of Bone Oncology202026100334. (https:\/\/doi.org\/10.1016\/j.jbo.2020.100334)"},{"key":"bib19","series-title":"American Journal of Clinical Oncology","first-page":"505","article-title":"Radiotherapy in the management of giant cell tumor of bone","volume":"36","author":"Shi","year":"2013","unstructured":"Shi WIndelicato DJReith JSmith KBMorris CGScarborough MTGibbs CPMendenhall WM & Zlotecki RA. Radiotherapy in the management of giant cell tumor of bone. American Journal of Clinical Oncology201336505\u2013508. (https:\/\/doi.org\/10.1097\/COC.0b013e3182568fb6)"},{"key":"bib20","series-title":"Clinical Orthopaedics and Related Research","first-page":"207","article-title":"Radiation therapy for giant cell tumors of bone","volume":"411","author":"Feigenberg","year":"2003","unstructured":"Feigenberg SJMarcus RBJrZlotecki RAScarborough MTBerrey BH & Enneking WF. Radiation therapy for giant cell tumors of bone. Clinical Orthopaedics and Related Research2003411207\u2013216. (https:\/\/doi.org\/10.1097\/01.blo.0000069890.31220.b4)"},{"key":"bib21","series-title":"Connective Tissue Research","first-page":"439","article-title":"Comparison of the anti-tumor effects of denosumab and zoledronic acid on the neoplastic stromal cells of giant cell tumor of bone","volume":"54","author":"Lau","year":"2013","unstructured":"Lau CPHuang LWong KC & Kumta SM. Comparison of the anti-tumor effects of denosumab and zoledronic acid on the neoplastic stromal cells of giant cell tumor of bone. Connective Tissue Research201354439\u2013449. (https:\/\/doi.org\/10.3109\/03008207.2013.848202)"},{"key":"bib22","series-title":"Lancet. Oncology","first-page":"275","article-title":"Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study","volume":"11","author":"Thomas","year":"2010","unstructured":"Thomas DHenshaw RSkubitz KChawla SStaddon ABlay JYRoudier MSmith JYe ZSohn W, Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Lancet. Oncology201011275\u2013280. (https:\/\/doi.org\/10.1016\/S1470-2045(1070010-3)"},{"key":"bib23","series-title":"Lancet. Oncology","first-page":"901","article-title":"Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study","volume":"14","author":"Chawla","year":"2013","unstructured":"Chawla SHenshaw RSeeger LChoy EBlay JYFerrari SKroep JGrimer RReichardt PRutkowski P, Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study. Lancet. Oncology201314901\u2013908. (https:\/\/doi.org\/10.1016\/S1470-2045(1370277-8)"},{"key":"bib24","series-title":"Lancet. Oncology","first-page":"1719","article-title":"Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study","volume":"20","author":"Chawla","year":"2019","unstructured":"Chawla SBlay JYRutkowski PLe Cesne AReichardt PGelderblom HGrimer RJChoy ESkubitz KSeeger L, Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study. Lancet. Oncology2019201719\u20131729. (https:\/\/doi.org\/10.1016\/S1470-2045(1930663-1)"},{"key":"bib25","series-title":"Clinical Orthopaedics and Related Research","first-page":"2522","article-title":"Is a short-course of preoperative denosumab as effective as prolonged therapy for giant cell tumor of bone?","volume":"478","author":"Hindiskere","year":"2020","unstructured":"Hindiskere SErrani CDoddarangappa SRamaswamy VRai M & Chinder PS. Is a short-course of preoperative denosumab as effective as prolonged therapy for giant cell tumor of bone?Clinical Orthopaedics and Related Research20204782522\u20132533. (https:\/\/doi.org\/10.1097\/CORR.0000000000001285)"},{"key":"bib26","series-title":"Annals of Surgical Oncology","first-page":"2860","article-title":"Surgical downstaging in an open-label phase II trial of denosumab in patients with giant cell tumor of bone","volume":"22","author":"Rutkowski","year":"2015","unstructured":"Rutkowski PFerrari SGrimer RJStalley PDDijkstra SPPienkowski AVaz GWunder JSSeeger LLFeng A, Surgical downstaging in an open-label phase II trial of denosumab in patients with giant cell tumor of bone. Annals of Surgical Oncology2015222860\u20132868. (https:\/\/doi.org\/10.1245\/s10434-015-4634-9)"},{"key":"bib27","series-title":"Bone and Joint Journal","first-page":"184","article-title":"The role of denosumab in joint preservation for patients with giant cell tumour of bone","volume":"103\u2013B","author":"Perrin","year":"2021","unstructured":"Perrin DLVisgauss JDWilson DAGriffin AMAbdul Razak ARFerguson PC & Wunder JS. The role of denosumab in joint preservation for patients with giant cell tumour of bone. Bone and Joint Journal2021103\u2013B184\u2013191. (https:\/\/doi.org\/10.1302\/0301-620X.103B1.BJJ-2020-0274.R1)"},{"key":"bib28","series-title":"Orthopaedic Surgery","first-page":"1101","article-title":"Short-term preoperative denosumab with surgery in unresectable or recurrent giant cell tumor of bone","volume":"11","author":"Zhang","year":"2019","unstructured":"Zhang RZMa TXQi DWZhao MHu T & Zhang GC. Short-term preoperative denosumab with surgery in unresectable or recurrent giant cell tumor of bone. Orthopaedic Surgery2019111101\u20131108. (https:\/\/doi.org\/10.1111\/os.12561)"},{"key":"bib29","series-title":"World Journal of Surgical Oncology","first-page":"281","article-title":"Risks and benefits of combining denosumab and surgery in giant cell tumor of bone - a case series","volume":"14","author":"M\u00fcller","year":"2016","unstructured":"M\u00fcller DABeltrami GScoccianti GCampanacci DAFranchi A & Capanna R. Risks and benefits of combining denosumab and surgery in giant cell tumor of bone - a case series. World Journal of Surgical Oncology201614281. (https:\/\/doi.org\/10.1186\/s12957-016-1034-y)"},{"key":"bib30","series-title":"Journal of Orthopaedic Surgery (Hong Kong)","first-page":"2309499020979750","article-title":"The current standing on the use of denosumab in giant cell tumour of the bone","volume":"28","author":"Singh","year":"2020","unstructured":"Singh VA & Puri A. The current standing on the use of denosumab in giant cell tumour of the bone. Journal of Orthopaedic Surgery (Hong Kong)2020282309499020979750. (https:\/\/doi.org\/10.1177\/2309499020979750)"},{"key":"bib31","series-title":"Clinical Orthopaedics and Related Research","first-page":"1783","article-title":"Preoperative denosumab with curettage and cryotherapy in giant cell tumor of bone: is there an increased risk of local recurrence?","volume":"476","author":"Scoccianti","year":"2018","unstructured":"Scoccianti GTotti FScorianz MBaldi GRoselli GBeltrami GFranchi ACapanna R & Campanacci DA. Preoperative denosumab with curettage and cryotherapy in giant cell tumor of bone: is there an increased risk of local recurrence?Clinical Orthopaedics and Related Research20184761783\u20131790. (https:\/\/doi.org\/10.1007\/s11999.0000000000000104)"},{"key":"bib32","series-title":"Journal of Bone and Joint Surgery. American Volume","first-page":"496","article-title":"Denosumab may increase the risk of local recurrence in patients with giant-cell tumor of bone treated with curettage","volume":"100","author":"Errani","year":"2018","unstructured":"Errani CTsukamoto SLeone GRighi AAkahane MTanaka Y & Donati DM. Denosumab may increase the risk of local recurrence in patients with giant-cell tumor of bone treated with curettage. Journal of Bone and Joint Surgery. American Volume2018100496\u2013504. (https:\/\/doi.org\/10.2106\/JBJS.17.00057)"},{"key":"bib33","series-title":"Clinical Orthopaedics and Related Research","first-page":"1076","article-title":"Is treatment with denosumab associated with local recurrence in patients with giant cell tumor of bone treated with curettage? A systematic review","volume":"478","author":"Tsukamoto","year":"2020","unstructured":"Tsukamoto STanaka YMavrogenis AFKido AKawaguchi M & Errani C. Is treatment with denosumab associated with local recurrence in patients with giant cell tumor of bone treated with curettage? A systematic review. Clinical Orthopaedics and Related Research20204781076\u20131085. (https:\/\/doi.org\/10.1097\/CORR.0000000000001074)"},{"key":"bib34","series-title":"Bone and Joint Journal","first-page":"1626","article-title":"Prognostic factors for local recurrence in extremity-located giant cell tumours of bone with pathological fracture","volume":"100\u2013B","author":"Medellin","year":"2018","unstructured":"Medellin MRFujiwara TTillman RMJeys LMGregory JStevenson JDParry M & Abudu A. Prognostic factors for local recurrence in extremity-located giant cell tumours of bone with pathological fracture. Bone and Joint Journal2018100\u2013B1626\u20131632. (https:\/\/doi.org\/10.1302\/0301-620X.100B12.BJJ-2018-0189.R2)"},{"key":"bib35","series-title":"European Journal of Surgical Oncology","first-page":"1384","article-title":"Denosumab treatment of inoperable or locally advanced giant cell tumor of bone - Multicenter analysis outside clinical trial","volume":"44","author":"Rutkowski","year":"2018","unstructured":"Rutkowski PGaston LBorkowska AStacchiotti SGelderblom HBaldi GGPalmerini ECasali PGronchi AParry M, Denosumab treatment of inoperable or locally advanced giant cell tumor of bone - Multicenter analysis outside clinical trial. European Journal of Surgical Oncology2018441384\u20131390. (https:\/\/doi.org\/10.1016\/j.ejso.2018.03.020)"},{"key":"bib36","series-title":"BMC Musculoskeletal Disorders","first-page":"256","article-title":"Pre-operative denosumab is associated with higher risk of local recurrence in giant cell tumor of bone: a systematic review and meta-analysis","volume":"21","author":"Chen","year":"2020","unstructured":"Chen XLi HZhu SWang Y & Qian W. Pre-operative denosumab is associated with higher risk of local recurrence in giant cell tumor of bone: a systematic review and meta-analysis. BMC Musculoskeletal Disorders202021256. (https:\/\/doi.org\/10.1186\/s12891-020-03294-2)"},{"key":"bib37","series-title":"Clinical Orthopaedics and Related Research","first-page":"1773","article-title":"Does denosumab change the giant cell tumor treatment strategy? Lessons learned from early experience","volume":"476","author":"Agarwal","year":"2018","unstructured":"Agarwal MGGundavda MKGupta R & Reddy R. Does denosumab change the giant cell tumor treatment strategy? Lessons learned from early experience. Clinical Orthopaedics and Related Research20184761773\u20131782. (https:\/\/doi.org\/10.1007\/s11999.0000000000000243)"},{"key":"bib38","series-title":"European Spine Journal","first-page":"257","article-title":"Denosumab in the treatment of giant cell tumor of the spine. Preliminary report, review of the literature and protocol proposal","volume":"29","author":"Boriani","year":"2020","unstructured":"Boriani SCecchinato RCuzzocrea FBandiera SGambarotti M & Gasbarrini A. Denosumab in the treatment of giant cell tumor of the spine. Preliminary report, review of the literature and protocol proposal. European Spine Journal202029257\u2013271. (https:\/\/doi.org\/10.1007\/s00586-019-05997-0)"},{"key":"bib39","series-title":"Annals of Oncology","first-page":"1520","article-title":"Bone sarcomas: ESMO-EURACAN-GENTURIS-ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"32","author":"Strauss","year":"2021","unstructured":"Strauss SJFrezza AMAbecassis NBajpai JBauer SBiagini RBielack SBlay JYBolle SBonvalot S, Bone sarcomas: ESMO-EURACAN-GENTURIS-ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology2021321520\u20131536. (https:\/\/doi.org\/10.1016\/j.annonc.2021.08.1995)"},{"key":"bib40","series-title":"European Journal of Cancer","first-page":"118","article-title":"Denosumab in advanced\/unresectable giant-cell tumour of bone (GCTB): for how long?","volume":"76","author":"Palmerini","year":"2017","unstructured":"Palmerini EChawla NSFerrari SSudan MPicci PMarchesi ELeopardi MPSyed ISankhala KKParthasarathy P, Denosumab in advanced\/unresectable giant-cell tumour of bone (GCTB): for how long?European Journal of Cancer201776118\u2013124. (https:\/\/doi.org\/10.1016\/j.ejca.2017.01.028)"},{"key":"bib41","series-title":"Clinical Sarcoma Research","first-page":"15","article-title":"Current status and unanswered questions on the use of denosumab in giant cell tumor of bone","volume":"6","author":"Gaston","year":"2016","unstructured":"Gaston CLGrimer RJParry MStacchiotti SDei Tos APGelderblom HFerrari SBaldi GGJones RLChawla S, Current status and unanswered questions on the use of denosumab in giant cell tumor of bone. Clinical Sarcoma Research2016615. (https:\/\/doi.org\/10.1186\/s13569-016-0056-0)"},{"key":"bib42","series-title":"Cancers (Basel)","first-page":"5758","article-title":"Progress on denosumab use in giant cell tumor of bone: dose and duration of therapy","volume":"14","author":"Xiang","year":"2022","unstructured":"Xiang FLiu HDeng JMa W & Chen Y. Progress on denosumab use in giant cell tumor of bone: dose and duration of therapy. Cancers (Basel)2022145758. (https:\/\/doi.org\/10.3390\/cancers14235758)"},{"key":"bib43","series-title":"Journal of Clinical Oncology","first-page":"4431","article-title":"Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases","volume":"25","author":"Lipton","year":"2007","unstructured":"Lipton ASteger GGFigueroa JAlvarado CSolal-Celigny PBody JJde Boer RBerardi RGascon PTonkin KS, Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. Journal of Clinical Oncology2007254431\u20134437. (https:\/\/doi.org\/10.1200\/JCO.2007.11.8604)"},{"key":"bib44","series-title":"Reproductive Toxicology","first-page":"27","article-title":"Reproductive toxicity of denosumab in cynomolgus monkeys","volume":"42","author":"Bussiere","year":"2013","unstructured":"Bussiere JLPyrah IBoyce RBranstetter DLoomis MAndrews-Cleavenger DFarman CElliott G & Chellman G. Reproductive toxicity of denosumab in cynomolgus monkeys. Reproductive Toxicology20134227\u201340. (https:\/\/doi.org\/10.1016\/j.reprotox.2013.07.018)"},{"key":"bib45","series-title":"BMC Musculoskeletal Disorders","first-page":"456","article-title":"Aneurysmal bone cyst: results of an off label treatment with denosumab","volume":"20","author":"D\u00fcrr","year":"2019","unstructured":"D\u00fcrr HRGrahneis FBaur-Melnyk AKn\u00f6sel TBirkenmaier CJansson V & Klein A. Aneurysmal bone cyst: results of an off label treatment with denosumab. BMC Musculoskeletal Disorders201920456. (https:\/\/doi.org\/10.1186\/s12891-019-2855-y)"},{"key":"bib46","series-title":"Nature","first-page":"315","article-title":"OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lyph-node organogenesis","volume":"397","author":"Kong","year":"1999","unstructured":"Kong YYYoshida HSarosi ITan HLTimms ECapparelli CMorony SOliveira-dos-Santos AJVan GItie A, OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lyph-node organogenesis. Nature1999397315\u2013323. (https:\/\/doi.org\/10.1038\/16852)"},{"key":"bib47","series-title":"Lancet","first-page":"539","article-title":"Osteosclerosis induced by denosumab","volume":"385","author":"Kobayashi","year":"2015","unstructured":"Kobayashi E & Setsu N. Osteosclerosis induced by denosumab. Lancet2015385539. (https:\/\/doi.org\/10.1016\/S0140-6736(1461338-6)"},{"key":"bib48","series-title":"Journal of Clinical Endocrinology and Metabolism","first-page":"891","article-title":"Effects of denosumab treatment and discontinuation on human growth plates","volume":"99","author":"Wang","year":"2014","unstructured":"Wang HDBoyce AMTsai JYGafni RIFarley FAKasa-Vubu JZMolinolo AA & Collins MT. Effects of denosumab treatment and discontinuation on human growth plates. Journal of Clinical Endocrinology and Metabolism201499891\u2013897. (https:\/\/doi.org\/10.1210\/jc.2013-3081)"},{"key":"bib49","series-title":"Translational Pediatrics","first-page":"470","article-title":"Denosumab in pediatric bone disorders and the role of RANKL blockade: a narrative review","volume":"12","author":"Wang","year":"2023","unstructured":"Wang DTang XShi QWang RJi TTang X & Guo W. Denosumab in pediatric bone disorders and the role of RANKL blockade: a narrative review. Translational Pediatrics202312470\u2013486. (https:\/\/doi.org\/10.21037\/tp-22-276)"},{"key":"bib50","series-title":"Journal of Clinical Endocrinology and Metabolism","first-page":"596","article-title":"Osteonecrosis of the jaw and rebound hypercalcemia in young people treated with denosumab for giant cell tumor of bone","volume":"103","author":"Uday","year":"2018","unstructured":"Uday SGaston CLRogers LParry MJoffe JPearson JSutton DGrimer R & H\u00f6gler W. Osteonecrosis of the jaw and rebound hypercalcemia in young people treated with denosumab for giant cell tumor of bone. Journal of Clinical Endocrinology and Metabolism2018103596\u2013603. (https:\/\/doi.org\/10.1210\/jc.2017-02025)"},{"key":"bib51","series-title":"Dahlin's Bone Tumors: General Aspects and Data on 10,165 Cases","author":"Unni","year":"2010","unstructured":"Unni KKInwards CY & Dahlin DC. Dahlin's Bone Tumors: General Aspects and Data on 10,165 Cases, 6th ed.Philadelphia,PA: Lippincott Williams and Wilkins2010."},{"key":"bib52","series-title":"Cancer","first-page":"2520","article-title":"Malignancy in giant cell tumor of bone","volume":"97","author":"Bertoni","year":"2003","unstructured":"Bertoni FBacchini P & Staals EL. Malignancy in giant cell tumor of bone. Cancer2003972520\u20132529. (https:\/\/doi.org\/10.1002\/cncr.11359)"},{"key":"bib53","series-title":"Clinical Orthopaedics and Related Research","first-page":"3050","article-title":"A high-grade sarcoma arising in a patient with recurrent benign giant cell tumor of the proximal tibia while receiving treatment with denosumab","volume":"473","author":"Aponte-Tinao","year":"2015","unstructured":"Aponte-Tinao LAPiuzzi NSRoitman P & Farfalli GL. A high-grade sarcoma arising in a patient with recurrent benign giant cell tumor of the proximal tibia while receiving treatment with denosumab. Clinical Orthopaedics and Related Research20154733050\u20133055. (https:\/\/doi.org\/10.1007\/s11999-015-4249-2)"},{"key":"bib54","series-title":"Cureus","first-page":"e3792","article-title":"Malignant sarcomatous transformation of benign giant cell tumor of bone after treatment with denosumab therapy: a literature review of reported cases","volume":"10","author":"Alaqaili","year":"2018","unstructured":"Alaqaili SIAbduljabbar AMAltaho AJKhan AA & Alherabi JA. Malignant sarcomatous transformation of benign giant cell tumor of bone after treatment with denosumab therapy: a literature review of reported cases. Cureus201810e3792. (https:\/\/doi.org\/10.7759\/cureus.3792)"},{"key":"bib55","series-title":"BMC Cancer","first-page":"89","article-title":"Malignancy in giant cell tumor of bone: analysis of an open-label phase 2 study of denosumab","volume":"21","author":"Palmerini","year":"2021","unstructured":"Palmerini ESeeger LLGambarotti MRighi AReichardt PBukata SBlay JYDai TJandial D & Picci P. Malignancy in giant cell tumor of bone: analysis of an open-label phase 2 study of denosumab. BMC Cancer20212189. (https:\/\/doi.org\/10.1186\/s12885-020-07739-8)"},{"key":"bib56","series-title":"International Journal of Molecular Sciences","first-page":"10721","article-title":"Malignant transformation of giant cell tumour of bone: a review of literature and the experience of a referral centre","volume":"23","author":"Vari","year":"2022","unstructured":"Vari SRiva FOnesti CECosimati ARenna DBiagini RBaldi JZoccali CAnelli VAnnovazzi A, Malignant transformation of giant cell tumour of bone: a review of literature and the experience of a referral centre. International Journal of Molecular Sciences20222310721. (https:\/\/doi.org\/10.3390\/ijms231810721)"},{"key":"bib57","series-title":"Scientific Reports","first-page":"5709","article-title":"Profiling of three H3F3A-mutated and denosumab-treated giant cell tumors of bone points to diverging pathways during progression and malignant transformation","volume":"11","author":"Hasenfratz","year":"2021","unstructured":"Hasenfratz MMellert KMarienfeld Rvon Baer ASchultheiss MRoitman PDAponte-Tinao LALehner BM\u00f6ller PMechtersheimer G, Profiling of three H3F3A-mutated and denosumab-treated giant cell tumors of bone points to diverging pathways during progression and malignant transformation. Scientific Reports2021115709. (https:\/\/doi.org\/10.1038\/s41598-021-85319-x)"},{"key":"bib58","series-title":"Current Opinion in Oncology","first-page":"332","article-title":"Current concepts in the treatment of giant cell tumour of bone","volume":"32","author":"van der Heijden","year":"2020","unstructured":"van der Heijden LDijkstra Svan de Sande M & Gelderblom H. Current concepts in the treatment of giant cell tumour of bone. Current Opinion in Oncology202032332\u2013338. (https:\/\/doi.org\/10.1097\/CCO.0000000000000645)"},{"key":"bib59","series-title":"Cancers (Basel)","first-page":"3543","article-title":"New target for precision medicine treatment of giant-cell tumor of bone: sunitinib is effective in the treatment of neoplastic stromal cells with activated PDGFR\u03b2 signaling","volume":"13","author":"Mahdal","year":"2021","unstructured":"Mahdal MNeradil JMudry PPaukovcekova SStaniczkova Zambo IUrban JMacsek PPazourek LTomas T & Veselska R. New target for precision medicine treatment of giant-cell tumor of bone: sunitinib is effective in the treatment of neoplastic stromal cells with activated PDGFR\u03b2 signaling. Cancers (Basel)2021133543. (https:\/\/doi.org\/10.3390\/cancers13143543)"},{"key":"bib60","series-title":"Medicine (Baltimore)","first-page":"e17778","article-title":"Denosumab and sunitinib in the treatment of giant-cell tumor of bone with pulmonary and bone metastases in an adolescent: a case report","volume":"98","author":"Wang","year":"2019","unstructured":"Wang GJiang SLi Z & Dong Y. Denosumab and sunitinib in the treatment of giant-cell tumor of bone with pulmonary and bone metastases in an adolescent: a case report. Medicine (Baltimore)201998e17778. (https:\/\/doi.org\/10.1097\/MD.0000000000017778)"},{"key":"bib61","series-title":"Oncologist","first-page":"889","article-title":"Adjuvant zoledronic acid in high-risk giant cell tumor of bone: a multicenter randomized Phase II trial","volume":"24","author":"Lipplaa","year":"2019","unstructured":"Lipplaa AKroep JRvan der Heijden LJutte PCHogendoorn PCWDijkstra S & Gelderblom H. Adjuvant zoledronic acid in high-risk giant cell tumor of bone: a multicenter randomized Phase II trial. Oncologist201924889\u2013e421. (https:\/\/doi.org\/10.1634\/theoncologist.2019-0280)"},{"key":"bib62","series-title":"Journal of Oral and Maxillofacial Surgery","first-page":"775","article-title":"Denosumab as a treatment alternative for central giant cell granuloma: a long-term retrospective cohort study","volume":"76","author":"Bredell","year":"2018","unstructured":"Bredell MRordorf TKroiss SR\u00fccker MZweifel DF & Rostetter C. Denosumab as a treatment alternative for central giant cell granuloma: a long-term retrospective cohort study. Journal of Oral and Maxillofacial Surgery201876775\u2013784. (https:\/\/doi.org\/10.1016\/j.joms.2017.09.013)"},{"key":"bib63","series-title":"Journal of Oral and Maxillofacial Surgery","first-page":"1301","article-title":"Alternative pharmacologic therapy for aggressive central giant cell granuloma: denosumab","volume":"72","author":"Schreuder","year":"2014","unstructured":"Schreuder WHCoumou AWKessler PA & de Lange J. Alternative pharmacologic therapy for aggressive central giant cell granuloma: denosumab. Journal of Oral and Maxillofacial Surgery2014721301\u20131309. (https:\/\/doi.org\/10.1016\/j.joms.2014.02.017)"},{"key":"bib64","series-title":"Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology","first-page":"e191","article-title":"Aggressive giant cell lesion of the jaws: a review of management options and report of a mandibular lesion treated with denosumab","volume":"120","author":"O'Connell","year":"2015","unstructured":"O'Connell JEBowe CMurphy CToner M & Kearns GJ. Aggressive giant cell lesion of the jaws: a review of management options and report of a mandibular lesion treated with denosumab. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology2015120e191\u2013e198. (https:\/\/doi.org\/10.1016\/j.oooo.2015.07.011)"},{"key":"bib65","series-title":"JBMR Plus","first-page":"101","article-title":"Improvement of giant cell lesions of the jaw treated with high and low doses of denosumab: a case series","volume":"1","author":"Kim","year":"2017","unstructured":"Kim TSUsera GLRuggiero SL & Weinerman SA. Improvement of giant cell lesions of the jaw treated with high and low doses of denosumab: a case series. JBMR Plus20171101\u2013106. (https:\/\/doi.org\/10.1002\/jbm4.10010)"},{"key":"bib66","series-title":"Bone","first-page":"115048","article-title":"Off-label uses of denosumab in metabolic bone diseases","volume":"129","author":"Polyzos","year":"2019","unstructured":"Polyzos SAMakras PTournis S & Anastasilakis AD. Off-label uses of denosumab in metabolic bone diseases. Bone2019129115048. (https:\/\/doi.org\/10.1016\/j.bone.2019.115048)"},{"key":"bib67","series-title":"Journal of Bone Oncology","first-page":"100384","article-title":"Current strategies for the treatment of solitary and aneurysmal bone cysts: a review of the literature","volume":"30","author":"Deventer","year":"2021","unstructured":"Deventer NDeventer NGosheger Gde Vaal MVogt B & Budny T. Current strategies for the treatment of solitary and aneurysmal bone cysts: a review of the literature. Journal of Bone Oncology202130100384. (https:\/\/doi.org\/10.1016\/j.jbo.2021.100384)"},{"key":"bib68","series-title":"Cureus","first-page":"e3989","article-title":"Denosumab therapy in the management of aneurysmal bone cysts: a comprehensive literature review","volume":"11","author":"Alhumaid","year":"2019","unstructured":"Alhumaid I & Abu-Zaid A. Denosumab therapy in the management of aneurysmal bone cysts: a comprehensive literature review. Cureus201911e3989. (https:\/\/doi.org\/10.7759\/cureus.3989)"},{"key":"bib69","series-title":"Tumori","first-page":"344","article-title":"Denosumab in patients with aneurysmal bone cysts: a case series with preliminary results","volume":"104","author":"Palmerini","year":"2018","unstructured":"Palmerini ERuggieri PAngelini ABoriani SCampanacci DMilano GMCesari MPaioli ALonghi AAbate ME, Denosumab in patients with aneurysmal bone cysts: a case series with preliminary results. Tumori2018104344\u2013351. (https:\/\/doi.org\/10.1177\/0300891618784808)"},{"key":"bib70","series-title":"Joint Bone Spine","first-page":"105260","article-title":"Denosumab in the management of Aneurysmal bone cyst","volume":"89","author":"Maximen","year":"2022","unstructured":"Maximen JRobin FTronchot ARossetti ARopars M & Guggenbuhl P. Denosumab in the management of Aneurysmal bone cyst. Joint Bone Spine202289105260. (https:\/\/doi.org\/10.1016\/j.jbspin.2021.105260)"}],"container-title":["EFORT Open Reviews"],"original-title":[],"link":[{"URL":"https:\/\/eor.bioscientifica.com\/view\/journals\/eor\/8\/12\/EOR-23-0138.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eor.bioscientifica.com\/downloadpdf\/journals\/eor\/8\/12\/EOR-23-0138.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/eor.bioscientifica.com\/downloadpdf\/journals\/eor\/8\/12\/EOR-23-0138.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T13:51:11Z","timestamp":1784555471000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.bioscientifica.com\/eor\/article\/8\/12\/895-905\/2598"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,1]]},"references-count":70,"journal-issue":{"issue":"12"},"URL":"https:\/\/doi.org\/10.1530\/eor-23-0138","relation":{},"ISSN":["2058-5241"],"issn-type":[{"value":"2058-5241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,1]]}}}